- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc stock price live, this page displays NASDAQ CLRB stock exchange data. View the CLRB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectar Biosciences Inc real time stock price chart below.
What Is the Cellectar Biosciences Inc Stock Price Today?
The Cellectar Biosciences Inc stock price today is 2.6000.
What Is the Stock Symbol for Cellectar Biosciences Inc?
The stock symbol for Cellectar Biosciences Inc is "CLRB."
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLRB quote. (ISIN: US15117F8804)
What Is the Cellectar Biosciences Inc Stock Price Today?
The Cellectar Biosciences Inc stock price today is 2.6000.
What Is the Stock Symbol for Cellectar Biosciences Inc?
The stock symbol for Cellectar Biosciences Inc is "CLRB."
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLRB quote. (ISIN: US15117F8804)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5000
2.6363
52 wk Range
2.2000
6.5200
CLRB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.50002.6363
52 wk Range
2.20006.5200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLRB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
11.5000
Upside
+342.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Form 4 Cellectar Biosciences Inc For: 8 July- Investing.com
Form 13G CELLECTAR BIOSCIENCES For: 5 June- Investing.com
- Cellectar Biosci receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Form 4 Cellectar Biosciences Inc For: 10 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.5000
(+342.31% Upside)
Cellectar Biosciences Inc Earnings Call Summary for Q2/2026
- Cellectar posted Q2 2026 loss of $0.57/share, missing analyst estimates of $0.48, though shares rose 3.85% on stronger cash position of $34M.
- Company secured financing providing $35M upfront with potential for $140M total capital through warrant tranches at $2.65 strike price.
- Site activation began for confirmatory Phase III Waldenstrom's macroglobulinemia study; FDA submission planned mid-2027 with 6-month review expected.
- Management targets 10-20 sites open with initial enrollment by submission; iopofosine showed 79.2% major response rate in post-BTK inhibitor cohort.
- R&D spending surged 92% to $4.6M as CLR 125 triple-negative breast cancer program dosed first patients; initial data expected late 2026 or early 2027.
Last Updated: 2026/08/13, 15:32
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0,57 / -0,48
Revenue / Forecast
-- / --
Compare CLRB to Peers and Sector
Metrics to compare | CLRB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLRBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −3.7x | −0.4x | |
PEG Ratio | −0.01 | 0.04 | 0.00 | |
Price/Book | 0.7x | 2.5x | 2.6x | |
Price / LTM Sales | - | 7.4x | 3.1x | |
Upside (Analyst Target) | 303.8% | 198.0% | 48.4% | |
Fair Value Upside | Unlock | 2.0% | 6.5% | Unlock |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Cellectar Biosciences (CLRB) Stock Price Today?
The Cellectar Biosciences stock price today is 2,6000 USD.
What Stock Exchange Does Cellectar Biosciences Trade On?
Cellectar Biosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cellectar Biosciences?
The stock symbol for Cellectar Biosciences is "CLRB."
What Is the Cellectar Biosciences Market Cap?
As of today, Cellectar Biosciences market cap is 19,8200M USD.
What Is Cellectar Biosciences's Earnings Per Share (TTM)?
The Cellectar Biosciences EPS (TTM) is -6,3455.
When Is the Next Cellectar Biosciences Earnings Date?
Cellectar Biosciences will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is CLRB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Cellectar Biosciences Stock Split?
Cellectar Biosciences has split 6 times.
How Many Employees Does Cellectar Biosciences Have?
Cellectar Biosciences has 11 employees.
What is the current trading status of Cellectar Biosciences (CLRB)?
As of Aug 15, 2026, Cellectar Biosciences (CLRB) is trading at a price of 2,6000 USD, with a previous close of 2,4800 USD. The stock has fluctuated within a day range of 2,5000 USD to 2,6363 USD, while its 52-week range spans from 2,2000 USD to 6,5200 USD.
What Is Cellectar Biosciences (CLRB) Price Target According to Analysts?
The average 12-month price target for Cellectar Biosciences is 11,5000 USD, with a high estimate of 15 USD and a low estimate of 10 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +342,31% Upside potential.
What Is the CLRB Premarket Price?
CLRB's last pre-market stock price is 2,5657 USD. The pre-market share volume is 20,0000, and the stock has decreased by 0,0857, or 3,4600%.
What Is the CLRB After Hours Price?
CLRB's last after hours stock price is 2,6300 USD, the stock has decreased by 0,0300, or 1,1500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.